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IMPORTANCE Mutations in the titin gene (TTN) cause a wide spectrum of genetic diseases.
The interpretation of the numerous rare variants identified in TTN is a difficult challenge given
its large size.
OBJECTIVE To identify genetic variants in titin in a cohort of patients with muscle disorders.
DESIGN, SETTING, AND PARTICIPANTS In this case series, 9 patients with titinopathy and 4
other patients with possibly disease-causing variants in TTNwere identified. Titin mutations
were detected through targeted resequencing performed on DNA from 504 patients with
muscular dystrophy, congenital myopathy, or other skeletal muscle disorders. Patients were
enrolled from 10 clinical centers in April 2012 to December 2013. All of them had not received
a diagnosis after undergoing an extensive investigation, including Sanger sequencing of
candidate genes. The data analysis was performed between September 2013 and January
2017. Sequencing data were analyzed using an internal custom bioinformatics pipeline.
MAIN OUTCOMES ANDMEASURES The identification of novel mutations in the TTN gene and
novel patients with titinopathy. We performed an evaluation of putative causative variants in
the TTN gene, combining genetic, clinical, and imaging data with messenger RNA and/or
protein studies.
RESULTS Of the 9 novel patients with titinopathy, 5 (55.5%) weremen and themean (SD) age
at onset was 25 (15.8) years (range, 0-46 years). Of the 4 other patients (3 men and 1 woman)
with possibly disease-causing TTN variants, 2 (50%) had a congenital myopathy and 2 (50%)
had a slowly progressive distal myopathy with onset in the second decade. Most of the
identified mutations were previously unreported. However, all the variants, even the already
describedmutations, require careful clinical andmolecular evaluation of probands and
relatives. Heterozygous truncating variants or uniquemissense changes are not sufficient to
make a diagnosis of titinopathy.
CONCLUSIONS AND RELEVANCE The interpretation of TTN variants often requires further
analyses, including a comprehensive evaluation of the clinical phenotype (deep phenotyping)
as well as messenger RNA and protein studies. We propose a specific workflow for the clinical
interpretation of genetic findings in titin.
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T he TTN gene encodes titin, a giant sarcomeric protein,spanning fromtheZ-disc to theM-band.1Titinplayscru-cial functional and structural roles in the sarcomere.2
Mutations in theTTN gene cause several differentmuscle dis-
orders, cardiomyopathies, and combinations of these.3,4
The skeletalmusclediseases causedbyTTNmutations in-
clude a wide spectrum of disorders.5 The late-onset autoso-
mal dominant tibial muscular dystrophy (TMD) is caused by
mutations in the last exon (364), which cause a posttransla-
tional pathological cleavage of a larger portion of the C-
terminal titin protein.6-8
Young- or early-adult–onset recessivedistal titinopathy is
due toeither2mutations in the last 2exons (363–364), or 1mu-
tation in these exons and a truncating mutation on the other
allele.9 Similarly, 2 C-terminal mutations or 1 C-terminal mu-
tation alongwith a truncating variant in trans cause an early-
onset recessive limb-girdle muscular dystrophy 2J.10-12
Othercongenitalorearly-onset recessivetitinopathiescom-
prisedisorderswithheterogeneousclinicalandhistological fea-
tures: congenital centronuclearmyopathy,13,14 early-onsetmy-
opathy with fatal cardiomyopathy,15 multiminicore disease
with heart disease,16 and childhood-juvenile–onset Emery-
Dreifuss–likemyopathyphenotypewithoutcardiomyopathy.17
Hereditary myopathy with early respiratory failure (HMERF)
represents an increasingly identified, completely different
adult-onset myopathy, mainly because of dominant muta-
tions in exon 344.18
Many additional TTN-related muscular phenotypes are
emerging as a consequence of next-generation sequencing
(NGS) screening in patients with myopathy.5 For instance,
adult-onset proximal lower limbweaknesswithout ankledor-
siflexion weakness has been described in 2 unrelated pa-
tientswhohadaTMD-causingmutation combinedwith a sec-
ondmissensemutation.9,19Recently, anovelTTNhomozygous
truncatingmutationwas found in apatientwith arthrogrypo-
sis multiplex congenita and severe axial hypotonia as a form
of congenital amyoplasiawithout cardiac involvement.20 The
mutation occurs within an exon, which seems to be ex-
pressed only in the fetal skeletal isoform.20
Next-generation sequencing is rapidly being imple-
mented into routine clinical practice, improving the diagnos-
tic rate for patients with neuromuscular diseases.21-23
Almost all NGS screenings reveal many rare and private titin
variants and their clinical interpretation is particularly
challenging.5,19,24-26 By using MotorPlex (Agilent Technolo-
gies), a targeted NGS panel, we screened TTN and the other
muscle disease genes in 504 patients with skeletal muscle
disorders.25,26Here,wedescribe theapproachused for theNGS
data interpretation and we propose a workflow for a more
straightforward and reproducible interpretation of the clini-
cal meaning of titin variants.
Methods
Patients
We recruited 504 European patients from 10 clinical centers,
mainly adults (mean [SD] age of recruitment, 39.04 [19.09]
years)with skeletalmuscle disorders. Thepatients hadnot re-
ceived diagnoses despite extensive diagnostic investigations
performed according to the observed phenotype. All the pa-
tients or their legal guardians providedwritten informed con-
sent. The study, approvedby the ethics committee of theUni-
versitá della Campania “Luigi Vanvitelli,” was performed in
accordance with the Declaration of Helsinki.
Molecular Analysis
GenomicDNAwasextracted fromtheperipheral bloodbyphe-
nol/chloroform purification. Next-generation sequencing li-
braries were prepared using MotorPlex, as previously
described.25,26 An in-house pipeline25-27 was used to analyze
the raw data.
We focusedonpatientswithpreviously reportedTTNmu-
tationsorwithat leastasingleTTN truncatingvariant.Missense
variantswere explicitly studied in a single large recessive fam-
ilyonly (familyX). Furtherpossible causativevariants ingenes
other than titinwere ruled out by a segregation analysis.
Titin gene mutated exons were amplified by polymerase
chainreactionusingM13-tailedprimers.M13primerswereused
toperformSanger sequencingusing anABIPRISM3130XLGe-
netic Analyzer (Applied Biosystems).
Direct-zol RNAMiniPrepKit (ZymoResearch)wasused to
extract RNA from muscle biopsies. Complementary DNA
(cDNA) synthesis was performed using RevertAid H Minus
Reverse Transcriptase (Thermo Scientific). Reverse-
transcriptionpolymerasechainreactionswereperformedusing
primers designed with Primer3 software and a DreamTaq
DNA Polymerase (Thermo Scientific). Copy number variant
analysiswasperformedusing a customarray-comparative ge-
nomichybridization,MotorChip28 (AgilentTechnologies). Se-
quence variants inTTN are described according to the coding
DNAreference sequence (LRG_391t1), covering transcript vari-
ant-IC (NM_001267550.1).
An in silico analysis of missense variants and the predic-
tion of their deleterious effectswere performed by homology
modeling in DeepView/Swiss-PdbViewer, version 4.1.0
(GlaxoSmithKlineR&DandSwiss InstituteofBioinformatics)29
using themost similar structures available in theProteinData
Bank for each titindomain.For titindomainsA168 toA170, the
Key Points
Question How can we interpret the variants identified in titin and
distinguish the pathogenic from the benign?
Findings In this case series, 504 patients with skeletal muscle
disorders were screened with a targeted resequencing approach.
An evaluation of titin gene variants that combined genetic, clinical,
and imaging data with messenger RNA and/or protein studies
identified 9 patients with a titinopathy and 4 patients with
possible titinopathy.
Meaning The clinical interpretation of titin gene variants is
challenging and requires comprehensive analyses. A specific
workflow for the clinical interpretation of genetic findings in titin is
suggested.
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crystal structure is available (2NZI).30 Themodels were visu-
alized using POV-Ray, version 3.7 (Persistence of Vision Ray-
tracer Pty Ltd); (http://www.povray.org).
Muscle Imaging, Histological Studies,
andWestern Blot Analysis
Musclemagnetic resonance imaging of the lower limbs using
1.5-Tmagnetic resonance scanners (SiemensandPhilips)31 and
histological and histochemical examinations inmuscle biop-
sies followed standardprocedures.32Westernblotting (WB)of
muscle biopsy samples was performed according to standard
methods.9 Twopreviously described in-house–generated an-
tibodies (rabbit polyclonal antibodyM10-111 andmousemono-
clonal antibody 11-4-39) were used to detect the titinM10 do-
main, followed by horseradish peroxidase–conjugated
secondary antibodies (Dako) and enhanced chemilumescent
detection using the Pierce SuperSignal West Femto substrate
(Thermo Fisher).9
Results
In an extensive study of 504 mainly adult, patients who had
not receivedageneticdiagnosisandwerepresentingwithclini-
cal signsofmusculardystrophy, congenitalmyopathy,orother
skeletalmuscledisorders,we identified9novelpatients (1.8%)
with titinopathyand4patients (0.8%)withvery likelydisease-
causingTTNmutations. The clinical details of eachpatient are
summarized in Table 1 and described in the eAppendix in the
Supplement.
PatientsWith Previously DescribedMutations
We identified disease-associated mutations in the TTN gene
in 3 patients (0.6%). Themost commonmutation responsible
for the HMERF phenotype (p.Cys31712Arg in exon 344)18 was
identified in 2 cases (I and II).
Patient Iwasaman inhis late50swithno familyhistory for
neuromusculardisorders.Hepresentedwithaprogressivedis-
talweakness in the lower limbs (onset at40years) anda restric-
tiverespiratoryinsufficiencyduetorespiratorymuscleweakness.
Patient II was aman in hismid-50s presentingwith a dis-
talmyopathy (onset in hismid-40swithmyalgia and exercise
intolerance). Although pulmonary function test results were
onlyminimally impaired,muscle biopsy results revealed typi-
cal histopathological features seen in HMERF, including cy-
toplasmic bodies and rimmed vacuoles.
ApreviouslyreportedTMDmutation(p.Ile35947Asn)33was
identified in compound heterozygosity with a nonsense mu-
tation in a Belgian woman in her early 40s (patient III). This
patienthas beendescribedelsewhere.34 Inbrief, she showsan
earlier onset (at 30 years) and amore severe phenotype com-
pared with previously reported patients with TMD who car-
ried the samemissense variant in heterozygosity.33
PatientsWith Biallelic Protein Truncating Variants
In 4 patients (0.8%), protein truncating variants (PTVs) were
identifiedonbothalleles. Inaman inhis early30swithhealthy
parents and siblings (patient IV), we found a splice site vari-
ant (c.107377 + 1G>A in intron 362) on thematernal allele and
a nonsense variant (p.Tyr21719* in exon 312) on the paternal
allele. Since childhood, thepatienthad shownmildlyprogres-
sive generalizedmuscular weakness. He received a diagnosis
of dilated cardiomyopathy without arrhythmias in his late
teens. Messenger RNA analyses confirmed the splicing effect
of the intronic variant (eFigure in the Supplement). Western
blotting analyses showed a reduced intensity of small C-
terminal titin protein fragments and the presence of an addi-
tional band due to the splicing defect (Figure 1).
A 34-year-old Belgian patient (patient V) with an unre-
markable familyhistoryharbored thep.Glu11945Argfs*6vari-
ant in exon 164 and the c.25063 + 1G>Avariant in intron87 in
compound heterozygosity. Since childhood, the patient had
shown a slowly progressive generalized muscular weakness
and gait abnormalities with frequent falling. In silico predic-
tions confirmed that c.25063 + 1G>A would result in a splic-
ingdefect. FurthermessengerRNAandWBanalyseswerenot
performed because of the unavailability of muscle tissue.
Two further biallelic PTVs were identified in patient VI
(p.Val26358Phefs*4 and p.Gln35879*, the latter recently
reported as a Balkan–Middle East founder mutation34,35)
and in 2 siblings (cases VIIa and VIIb) (p.Cys9322* and
p.Arg35800Glnfs*10).
Patient VI was a woman in her mid-50s presenting in her
early 30s with frequent tripping. Her family history was un-
remarkable. The disease worsened and the patient has re-
quired a cane to walk for the last 5 years. Echocardiography
results in her early 50s showed mild left ventricular hypoki-
nesia and a mildly reduced ejection fraction (43%).
The index case of familyVIIwas awoman inher early 50s
(VIIa), with onset in adulthood (in her early 30s) character-
ized bywalking difficulty and distal lower limbmuscleweak-
ness. No signs of respiratory or cardiac involvementwere de-
tected at a recent follow-up (2016). Patient VIIb, a sibling,
showed similar clinical and histological features.
PatientsWith a Single Heterozygous Protein
Truncating Variant
In 1additionalpatient (patientVIII)harboring theheterozygous
p.Arg35800Glnfs*10inexon363,proteinanalysisresultsshowed
asevere reductionwith theC-terminal titinantibodies, indicat-
ing truncatingmutationsonbothalleles aspreviously reported
in patients with limb-girdle muscular dystrophy 2J.9 No addi-
tionalvariantsweredetectedbyMotorPlex, andMotorChipdid
not reveal any copynumber variants. Thepatient hadpresent-
edwithdifficulties inrunningandAchilles’ tendoncontractures
since thepreteenyears. Theweakness in the lower extremities
worsened intheearly30s.Nosignsofcardiomyopathywerede-
tected on heart ultrasonography.
In family IX, the proband was a teenage boy who pre-
sented with hypotonia and congenital torticollis at birth. He
had delayed motor milestones, reaching independent walk-
ing after the toddler years. He was referred to the neuromus-
cular unit as a child because of a proximal and distal weak-
ness. The patient, as well as his similarly affected sibling,
harboredasingle-nucleotideduplication (p.Arg26562Thrfs*12)
on the maternal allele. In addition, 2 missense variants were
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identified on the paternal allele. In particular, a c.18970A>C
causing a substitution of a threonine with a proline at posi-
tion 6324 was identified. The mutated amino acid is located
on the external surface of a β strand in an Ig-domain in the I-
band region, probably affecting the stability (Figure 2A). The
second detected variant was a c.94015A>G leading to a sub-
stitutionof a threonine at position 31339with an alanine in an
Fn3 domain (A-band portion of titin). The amino acid substi-
tution may affect the interaction with ligands in this region
(Figure 2B). A comparative genomic hybridization array ex-
cluded the presence of copy number variants in the proband
andWBresults showeda reduced intensity of C-terminalM10
fragments (Figure 1B).
PatientsWith RareMissense Variants
Becauseraremissensevariantswerefoundinmostanalyzedpa-
tients,wefocusedonasinglerecessivefamily(familyX) inwhom
2 rare variants segregatedwith the observed phenotype.
The2patientsweresiblings (mid-40sandmid-50s, respec-
tively) and showed a slowly progressive distal myopathy with
Table 1. Clinical Summary of Index Patients
Variant
Patient
No./Sex/Onset,
Age/Current,
Age
First
Symptom
Muscle
Weakness CK
Muscle
Involvement
(MRI)
Biopsy
Findings
Cardiac
Impairment
Genotype
(LRG_391) Titinopathy
Previ-
ously
reported
variants
I/M/early 40s/
late 50s
Weakness and
toe-walking
Prox UL,
prox and
dist LL
NA GM, QD,
BF, PSM
Connective
increase, necrotic
fibers
None (c.95134T>C
p[.Cys31712Arg])
Confirmed
II/M/mid-40s/
mid-50s
Myalgia and
exercise
intolerance
Prox and
dist LL
2-3X NA Cytopl. bodies None (c.95134T>C
p.[Cys31712Arg])
III/F/early
30s/ early 40s
Walking
difficulties
Dist > prox
LL
N TA, EDL,
SOL
Atrophic fibers,
FTD
None (c.107840T>A
p.[Ile35947Asn]) +
(c.67519C>T
p.[Gln22507*])
Biallelic
PTVs
IV/M/child/ early
30s
Difficulty in
running and
toe-walking
Dist UL,
prox, and
dist LL
10X AM, BF,
SM, GST
Rimmed vacuoles,
FTD
DCM (c.107377 + 1G>A) +
(c.65157T>A
p.[Tyr21719*])
V/M/infant/ early
30s
Hypotonia Prox UL,
prox, and
dist LL
N GM, QD,
RF, BF, TA,
SOL, GST
FTD, internal
nuclei
None (c.35828dupA
p.[Glu11945Argfs*6]) +
(c.25063 + 1G>A)
VI/F/early
30s/ early 50s
Walking
difficulties
Dist LL 2X NA FTD, cores Ventricular
hypokinesia
and reduced
ejection
fraction
(c.79072delG
p.[Val26358Phefs*4]) +
(c.107635C>T
p.[Gln35879*])
VIIa/F/early 30s/
early 50s
Walking
difficulties
Dist LL NA TA, SOL,
GST
FTD, autophagic
vacuoles
NA (c.27966T>A
p.[Cys9322*])+
(c.107397dupC
p.[Arg35800Glnfs*10])
VIIb/F/early 30s/
early 60s
Walking
difficulties
Dist LL NA NA FTD, autophagic
vacuoles
Paroxysmal
sinus
tachycardias
and frequent
ventricular
extrasystoles
(c.27966T>A
p.[Cys9322*]) +
(c.107397dupC
p.[Arg35800GInfs*10])
Monoal-
lelic PTV
VIII/M/preteen/
late 40s
Difficulty in
running
Pectoralis
and LL
2-3X BF, SM, ST,
GM, IP and
TA
FTD, internal
nuclei
None (c.107397dupC
p.[Arg35800Glnfs*10]) + ?
IXa/M/infant/
teenage
Hypotonia Prox and
dist UL
and LL
N NA FTD, minicores NA (c.79683dupA
p.[Arg26562Thrfs*12]) +
(c.94015A>G
p.[Thr31339Ala];
c.18970A>C
p.[Thr6324Pro])
Possible
IXb/F/infant/
teenage
Hypotonia Prox and
dist UL
and LL
N NA NA NA (c.79683dupA
p.[Arg26562Thrfs*12]) +
(c.94015A>G
p.[Thr31339Ala];
c.18970A>C
p.[Thr6324Pro])
Missense
variants
Xa/M/teenage/
early 50s
Difficulty in
running
Dist > prox
LL
N TA and SOL FTD, autophagic
vacuoles
None (c.100585T>C
p.[Trp33529Arg]) +
(c.98390A>G
p.[Asn32797Ser])
Xb/M/teenage/
early 40s
Difficulty in
running
Dist>Prox LL N TA and SOL FTD, autophagic
vacuoles
None (c.100585T>C
p.[Trp33529Arg]) +
(c.98390A>G
p.[Asn32797Ser])
Abbreviations: AM, adductor magnus; BF, biceps femoris; CK, creatine kinase; Cytopl bodies, cytoplasmic bodies; DCM, dilated cardiomyopathy; Dist, distal;
EDL, extensor digitorum longus; F, female; FTD, fiber-type disproportion; GM, gluteus maximus; GST, gastrocnemius; IP, iliopsoas; LL, lower limbs; M, male;
MRI, magnetic resonance imaging; NA, not available; Prox, proximal; PSM, paraspinal muscles; PTV, protein truncating variant; QD, quadriceps; RF, rectus femoris;
SM, semimembranosus; SOL, soleus; ST, semitendinosus; TA, tibialis anterior; UL, upper limbs.
Research Original Investigation Interpreting Genetic Variants in Titin in Patients With Muscle Disorders
E4 JAMANeurology Published online February 12, 2018 (Reprinted) jamaneurology.com
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a University of Florida User  on 02/13/2018
onset in theseconddecade.At the latestneurological examina-
tion, thepatientswalkedwithawaddlinggaitandbilateral step-
page.Their serumcreatinekinase levelswerenormal.Noheart
orrespiratoryinvolvementwasobserved.Bothsiblingsharbored
2compoundheterozygousmissensevariants:p.Asn32797Serand
p.Trp33529Arg. The former is located in an Fn3 domain in the
A-band portion of titin, and in silico studies predicted that the
aminoacid is locatedontheexternal surfaceof thedomain,pos-
sibly affecting the binding to the interactors. The latter variant
is inanIg-domain,whichis locatedjustbeforeSer/Thrkinasedo-
main (TK). The amino acid change probably affects the folding
of thedomain (Figure2).No further clearlyorpotentiallydam-
agingvariantsweredetectedbyMotorPlex(noteveninadditional
causativeorcandidategenes)andMotorChipstudiesdidnot re-
veal anycausativedeletionorduplication.A segregation study
confirmedthatnoneofthe3unaffectedsiblingswerecompound
heterozygousfor theseTTNmissensevariants.Westernblotting
results revealed a normal C-terminal titin pattern, as expected
(Figure 1).
Discussion
Becauseof itssize,manyrareorprivatevariantsareusually iden-
tified in the titingenebyNGSanalyses.5Thecorrect interpreta-
tionof thesevariants is a critical challenge formakingadiagno-
sis forpatientsaffectedbyneuromusculardisorders.5Although
mainlytruncatingmutationshavebeenidentifiedinpatientswith
titinopathy,missensevariantsmaysimilarlyhaveacrucial role,
as also suggested by our data (Figure 3).
For the interpretation of genetic findings inTTN,wehave
developed a workflow (Figure 3) based on 3 categories of se-
quence variants: (1) previously reported mutations, (2) trun-
cating variants, and (3) missense changes and on deep phe-
notyping (ie, a comprehensive and precise evaluation of
phenotypic abnormalities in which each component of the
clinical phenotype is observedanddescribed).36Although the
limited number of patients with titinopathy described so far
has hampered the identification of specific and unique hall-
marks foreachTTN-relateddisease, significantkeypointshave
been reported (Table 2). The integration of structured clinical
data with genetic variations is crucial for a correct evaluation
of TTN findings, as detailed below.
Previously ReportedMutations
If previously reported disease-causing mutations are identi-
fied, they may easily address the diagnosis of a titinopathy;
however, segregationstudiesandadeepphenotypingareman-
datory for a correct genotype-phenotype correlation and for
proper genetic counselling. In thepresence of a previously re-
ported HMERF variant (eg, p.Cys31712Arg), a respiratory in-
volvementand/or thepresenceofcytoplasmicbodiesandmyo-
fibrillar changes (seen inpatient I and II, respectively) confirm
the diagnosis of titinopathy.5,18
The clinical interpretation ofmutations in exon 364, pre-
viously associated with TMD (like the p.Ile35947Asn in pa-
tient III), is more complex. These mutations cause either a
dominant,mild, and late-onset distal leg phenotype, or reces-
sive phenotypes.7-9,11Muscle imaging ismandatory andoften
very informative (Table 2).
Figure 1. Western Blot for C-terminal Titin Fragments
Patients VIII and IVA Patients Xa and IXaB
kD
a
250
150
100
75
50
37
25
20
15
10
MyHC
Ctrl TMD LGMD2J VIII IV Ctrl TMD LGMD2J VIII IV Ctrl TMD LGMD2J Xa IXa Ctrl TMD LGMD2J Xa IXa
M10-1 11-4-3 M10-1 11-4-3
Western blotting using 2 different antibodies (M10-1 and 11-4-3) against the titin
C-terminal M10 domain. A, Patient VIII with a single identified protein
truncating variant shows a severe reduction of titin C-terminal fractions of all
sizes; patient IV presents a reduced amount of the small (<20 kDa) titin
fragments, and additionally the presence of a truncated fragment (arrowheads)
resulting from the aberrant splicing due to the splice site mutation in intron 362.
B, Patient Xa with missensemutations showed a normal titin C-terminal
pattern, while patient IXa with a single protein truncating variant and 2
missense variants showed a reduction of the small (<20 kDa) titin C-terminal
fragments in particular. Themyosin heavy chain (MyHC) serves as the loading
control. Ctrl indicates control; LGMD2J, limb-girdle muscular dystrophy 2J;
TMD, tibial muscular dystrophy.
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Protein Truncating Variants
Identifying 2 truncating variants in trans results in a diagno-
sis of titinopathy, which may be corroborated by aWB show-
ing the absence or a severe reduction of the C-terminal pro-
tein (patient IVor previously reportedpatients9,34). However,
a completemolecular characterizationofvariants affecting the
canonicalornoncanonical splice sitesbycDNAorprotein stud-
ies is suggested.
Biallelic truncatingmutations have been so far associated
withawide rangeofphenotypes, showingheterogeneousclini-
calandhistological features.However,aprimarycardiacinvolve-
ment is often seenandpeculiar imaging findings seemto char-
acterize congenital or early onset titinopathies.
Clinically evaluating single heterozygous truncating vari-
ants is more complex (Figure 3). Increasing evidence is indi-
cating that titin truncating variants cause recessive skeletal
muscledisorders.9,15,16,34 In thepresenceofmonoallelic PTVs,
we suggest performing aWBanalysis that represents themost
valuable andpotentially conclusive test, as it is the only avail-
able tool able to predict the presence of further elusive trun-
cating variants in trans (as seen in patient VIII and in a previ-
ously reported patient9).
Why are there elusive variants inTTN? First, the huge size
of theTTN gene and its complex structure, due to a 10-kb trip-
licate regionwhere 9 exons are repeated 3 times,may hamper
anexhaustivegeneanalysisbyNGS, resulting in low-coveredor
noncoveredregionsandthusinunidentifiedmutations.Second,
additional elusivemutationsmaybedeep intronicor structural
variants. Currently available bioinformatics tools37 combined
withcustomizedcomparativegenomichybridizationarrays28,38
Figure 2. Positions of TTNMissense Variants Identified in Families IX and X on a Structural Model
p.Trp33529ArgDp.Asn32797SerC
p.Thr31339AlaBp.Thr6324ProA
All images weremade in DeepView/Swiss-PdbViewer, version 4.1.0
(GlaxoSmithKline R&D and Swiss Institute of Bioinformatics). The computed
molecular surface is semitransparent gray and the secondary structure is shown
with yellow β strands and red α helices. Themutated residue is shown as CPK.
A, Position of p.Thr6324Pro using themost similar structure available in the
Protein Data Bank (3B43). Themutated residue is located in a β strand. The
mutation to proline will induce steric restrictions most probably causing a
reduced stability and a structural disruption. B, p.Thr31339Ala modeled using
the structure 2NZI of titin domains A168-A170. The change from threonine to
alanine is predicted in a loop and will probably not interfere with the structure.
However, the hydroxyl group on the sidechain of threonine allows for hydrogen
bonding with other molecules. The amino acid substitutionmay alter
interactions with TTN ligands in this specific region. C, Position of
p.Asn32797Ser using the structure 2NZI. Themutated amino acid, one of the
first residues in the domain, is on the surface of themodel and it seems not to
cause any important structural change. It will probably affect the binding to the
interactors of this domain. D, Position of p.Trp33529Arg using the structure
2JBO. The tryptophan residue p.Trp33529 is almost totally buried in the
hydrophobic core of the protein. The change to a positively charged arginine
will probably be detrimental for the structural stability and will lead to an
unfolding of this domain.
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Table 2. Features of Titin-Related Skeletal Musical Disorders
Dominant Inheritance Recessive Inheritance
Disease
HMERF TMD LGMD2J Adult-onset distal
myopathy
Proximal
adult-onset
rimmed
vacuolar
myopathy
Congenital or
early onset
titinopathies
Genetics
Heterozygous exon
344 mutations
Heterozygous
exon 364
mutations
Homozygosity (mainly exon
364 mutations)a Compound
heterozygosity (mainly exon
364 + truncating mutations)a
Compound
heterozygosity
(exon
364 +
missense
mutations)
Compound
heterozygosity
(mainly
truncating
variants)
Key Point(s)
Respiratory
muscle weakness;
“necklace”
cytoplasmic bodies
and myofibrillar
changes in muscle
biopsies
Degeneration of
the muscles of
the anterior
lower legs
starting in the
anterior tibial
muscle
Slowly progressive
fatty degeneration
(preserved muscles
can be found in
young patients)
Severe
degeneration of
tibialis anterior
and soleus
(unusual in TMD)
Prominent
quadriceps and
soleus
involvement
(sparing of
tibial muscle);
peculiar
rimmed
vacuoles in
their muscle
biopsies
Cardiac
involvement
often seen;
sparing of
extraocular
muscles; early
degeneration of
semitendinosus,
soleus, and
peroneal; late
involvement of
the rectus
femoris and vasti
a The clinical phenotype depends on
the specific exon 364mutation.
Figure 3. Schematic Representation ofMutations Identified and Algorithm for the Clinical Interpretation of Genetic Findings in Titin
Workflow for interpreting titin variantsB
Truncating and missense variantsA
Z-disk
I-band
A-band
M-band
Missense variant
Protein truncating variant
Exonic variant
Intronic variant
p.Thr6324Pro
c.25063+1G>A
p.Cys9322*
p.Glu11945Argfs*6
p.Arg26562Thrfs*12
p.Trp33529Arg
p.Gln22507* p.Cys31712Arg p.Arg35800Glnfs*10
p.Ile35947Asn
p.Val26358Phefs*4
c.107377+1G>A
p.Asn32797Ser
p.Thr31339Ala
p.Gln35879*
p.Tyr21719*
Reported
mutations
Truncating
variants
Missense
variants
Deep phenotyping
Segregation studies
Biallelic
Monoallelic
Deep phenotyping
Second-tier tests
Concordant
results
Deep phenotyping
Second-tier tests
Elusive
variant
Supporting
evidences
Yes
Yes
No
Yes
No
Diagnosis of 
titinopathy
Functional tests
Unrelated cases
Suspicion of 
titinopathy
Other diagnosis
No
A, Schematic visualization of truncating (circle) andmissense (triangle) variants
identified in TTN gene in this study. B, Workflow for interpreting titin variants.
Previously reported, disease-causingmutations in the TTN gene easily address
the diagnosis toward a titinopathy. Identifying 2 truncating variants on both the
alleles results in a diagnosis of titinopathy. A single heterozygous protein
truncating variant is not sufficient for a diagnosis of titinopathy. Missense
variants can lead to a diagnosis of titinopathy only when sufficient evidence
supporting their pathogenicity is obtained.
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should be used to assess the presence of large deletions or
duplications39 inunsolvedcases.Westernblotting isaneffective
strategy,althoughwithwell-recognizedlimitations. Inframede-
letions, the skippingof inframeexonsor truncating variants in
exonsnot expressed in the adultmuscles, and small size varia-
tionswould still not be recognizable by a titinWestern blot.
Several recent studies suggest thatheterozygous titin trun-
cating variants cause dominant dilated cardiomyopathy.40,41
However, a positional effect and an incomplete and age-
dependentpenetrance (probably related toothergeneticor en-
vironmental factors)mayexplain the lackof anycardiac symp-
tomsinsomeindividualswithmonoorbiallelicPTVs(eg,patient
VandVIII).41Asystematic follow-uptoevaluate thecardiacsta-
tus of such individuals, aswell as their asymptomatic relatives
who carry truncating variants, is highly recommended.
Missense Variants
The clinical significance of missense variants in TTN repre-
sents amajor issue related to NGS investigation in the field of
neuromusculardisorders.5AWBanalysis isnot effective in the
presenceofmissensevariants, asdemonstrated incases IXand
X. The evaluationofTTNmissense variants should reflect the
current genetic guidelines.42 A segregation analysis and/or in
silico predictions canonly suggest a pathogenic or a noncaus-
ative effect of a missense variant.42
In thepresenceofmonoallelic truncatingvariants, aswell
as of missense variants, the possible causative effect of mu-
tations ingenesother thantitinhas toberuledoutandthepres-
ence of the aforementioned key clinical points has to be as-
sessed by deep phenotyping.
However, the definitive proof of pathogenicity for mis-
sensevariants canonlybeestablishedby functional tests, seg-
regation studies in very large families, and/or identifying un-
related patients or families with the same mutations. The
interpretationofTTNmissensevariantsmayalsobenefit from
the establishment of clinical and research consortia able to
combine cohorts of patients into larger groups.43
Limitations
Our study has limitations. First, we enrolled, in amulticenter
study, patients with clinically and genetically heterogenous
conditions and specific clinical studies (magnetic resonance
imaging or cardiac tests) were unavailable or not performed
for some patients.
Second, we report missense variants with an uncon-
firmed causative role (cases IX andX). Although further stud-
ies are needed to attribute causality to missense changes, re-
porting possible causative variants is an effective strategy to
improve consistency in the interpretation of molecular find-
ings in titin. Ultimately, the proposed workflow is meant for
interpreting titin variants in a mendelian disorder. The pos-
sible role of titin variants as modifiers or within a digenic or
multigenic disease is not discussed here.
Conclusions
An increasingnumberof rare, ultrarare, andprivatevariants in
the titingene isdetected inanysequencingapproach, andNGS
hasdramaticallyexpandedthespectrumofskeletalmuscledis-
orders associatedwithcausativemutations inTTN.5Ourwork-
flowresults in agreaterunderstandingandmoreconsistent in-
terpretationof titinvariantsbyneurologists, pediatricians, and
geneticists less familiarwith the titin gene and titinopathies.
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